Edwards Lifesciences stock surged late Tuesday — and could retake its 50-day and 200-day lines — after beating fourth-quarter ...

(B) The Edwards Sapien™ (Edwards Lifesciences, Inc., CA, USA) valve is a balloon-expandable, bovine pericardial interventional aortic valve.

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. Investors remain bullish on ...

The signs of aortic stenosis on physical ... that has FDA approval is the Edwards SAPIEN valve with the Retroflex3 system. It is a trileaflet valve made from bovine pericardium in a stainless ...

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...

Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for patients with aortic stenosis who were too sick to undergo open heart surgery.

Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

A critical component of Edwards' success is its leadership in the $7 billion transcatheter aortic valve replacement (TAVR) market, where it holds over 50% market share. This segment generates roughly ...

Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests that recent conversations with six Transcatheter aortic valve replacement ...